{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:52:33Z","timestamp":1792644753140,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["CDA34110287"],"award-info":[{"award-number":["CDA34110287"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002733"],"award-info":[{"award-number":["UL1TR002733"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["63\/016,039"],"award-info":[{"award-number":["63\/016,039"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007520","name":"Nationwide Children's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006928","name":"Ohio State University","doi-asserted-by":"publisher","award":["UL1TR002733"],"award-info":[{"award-number":["UL1TR002733"]}],"id":[{"id":"10.13039\/100006928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.isci.2022.104001","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T12:08:51Z","timestamp":1646050131000},"page":"104001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Selective modulator of nuclear receptor PPAR\u03b3 with reduced adipogenic potential ameliorates experimental nephrotic syndrome"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4609-372X","authenticated-orcid":false,"given":"Claire","family":"Bryant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6877-4796","authenticated-orcid":false,"given":"Galen","family":"Rask","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda P.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina R.","family":"Galdino-Pitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica A.","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Cianciolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajgopal","family":"Govindarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Becknell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1756-8271","authenticated-orcid":false,"given":"Bryce A.","family":"Kerlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco A.R.","family":"Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Fornoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1111-9168","authenticated-orcid":false,"given":"Shipra","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2022.104001_bib1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/mol.111.071654","article-title":"Comparison of direct action of thiazolidinediones and glucocorticoids on renal podocytes: protection from injury and molecular effects","volume":"80","author":"Agrawal","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.isci.2022.104001_bib2","doi-asserted-by":"crossref","first-page":"24392","DOI":"10.1038\/srep24392","article-title":"Pioglitazone enhances the beneficial effects of glucocorticoids in experimental nephrotic syndrome","volume":"6","author":"Agrawal","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2022.104001_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41581-020-00339-6","article-title":"Nuclear receptors in podocyte biology and glomerular disease","volume":"17","author":"Agrawal","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.isci.2022.104001_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrneph.2017.155","article-title":"Dyslipidaemia in nephrotic syndrome: mechanisms and treatment","volume":"14","author":"Agrawal","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.isci.2022.104001_bib5","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.biopha.2017.01.091","article-title":"Reference genes for quantitative PCR in the adipose tissue of mice with metabolic disease","volume":"88","author":"Almeida-Oliveira","year":"2017","journal-title":"Biomed.Pharmacother."},{"key":"10.1016\/j.isci.2022.104001_bib6","doi-asserted-by":"crossref","first-page":"28169","DOI":"10.1074\/jbc.M111.332106","article-title":"GQ-16, a novel peroxisome proliferator-activated receptor gamma (PPARgamma) ligand, promotes insulin sensitization without weight gain","volume":"287","author":"Amato","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.isci.2022.104001_bib7","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.celrep.2018.10.035","article-title":"PPARgammaDelta5, a naturally occurring dominant-negative splice isoform, impairs PPAR gamma function and adipocyte differentiation","volume":"25","author":"Aprile","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2022.104001_bib8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00467-006-0026-5","article-title":"A case of unfulfilled expectations.Cytokines in idiopathic minimal lesion nephrotic syndrome","volume":"21","author":"Araya","year":"2006","journal-title":"Pediatr.Nephrol."},{"key":"10.1016\/j.isci.2022.104001_bib9","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00467-009-1214-x","article-title":"T regulatory cell function in idiopathic minimal lesion nephrotic syndrome","volume":"24","author":"Araya","year":"2009","journal-title":"Pediatr.Nephrol."},{"key":"10.1016\/j.isci.2022.104001_bib10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12882-017-0644-0","article-title":"Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report","volume":"18","author":"Awanami","year":"2017","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.isci.2022.104001_bib11","first-page":"1326","article-title":"Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats","volume":"47","author":"Buckingham","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.isci.2022.104001_bib12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fped.2015.00078","article-title":"The evidence-based approach to adult-onset idiopathic nephrotic syndrome","volume":"3","author":"Canetta","year":"2015","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.isci.2022.104001_bib13","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0049-3848(11)70007-X","article-title":"Thrombin generation tests","volume":"127","author":"Castoldi","year":"2011","journal-title":"Thromb.Res."},{"key":"10.1016\/j.isci.2022.104001_bib14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.isci.2022.104001_bib15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature10383","article-title":"Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation","volume":"477","author":"Choi","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.isci.2022.104001_bib16","doi-asserted-by":"crossref","first-page":"e0154310","DOI":"10.1371\/journal.pone.0154310","article-title":"GQ-16, a TZD-derived partial PPARgamma agonist, induces the expression of thermogenesis-related genes in Brown fat and visceral white fat and decreases visceral adiposity in obese and hyperglycemic mice","volume":"11","author":"Coelho","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2022.104001_bib17","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.1371\/journal.pone.0000898","article-title":"Evidence based selection of housekeeping genes","volume":"2","author":"de Jonge","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2022.104001_bib18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40259-017-0220-y","article-title":"PCSK9 inhibitors in hyperlipidemia: current status and clinical outlook","volume":"31","author":"Di Bartolo","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.isci.2022.104001_bib19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","article-title":"Nephrotic syndrome in childhood","volume":"362","author":"Eddy","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2022.104001_bib20","doi-asserted-by":"crossref","first-page":"18779","DOI":"10.1074\/jbc.272.30.18779","article-title":"The organization, promoter analysis, and expression of the human PPARgamma gene","volume":"272","author":"Fajas","year":"1997","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.isci.2022.104001_bib21","doi-asserted-by":"crossref","first-page":"6042162","DOI":"10.1155\/2016\/6042162","article-title":"PPARgene: a database of experimentally verified and computationally predicted PPAR target genes","volume":"2016","author":"Fang","year":"2016","journal-title":"PPAR Res."},{"key":"10.1016\/j.isci.2022.104001_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2022.104001_bib23","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.kint.2018.10.018","article-title":"Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"95","author":"Floege","year":"2019","journal-title":"Kidney Int."},{"key":"10.1016\/j.isci.2022.104001_bib24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.amjmed.2011.08.025","article-title":"The cardiovascular effects of peroxisome proliferator-activated receptor agonists","volume":"125","author":"Friedland","year":"2012","journal-title":"Am. J. Med."},{"key":"10.1016\/j.isci.2022.104001_bib25","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1186\/s12859-019-3251-1","article-title":"BISR-RNAseq: an efficient and scalable RNAseq analysis workflow with interactive report generation","volume":"20","author":"Gadepalli","year":"2019","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.isci.2022.104001_bib26","doi-asserted-by":"crossref","first-page":"38513","DOI":"10.1038\/srep38513","article-title":"Evaluation of candidate reference genes for RT-qPCR studies in three metabolism related tissues of mice after caloric restriction","volume":"6","author":"Gong","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2022.104001_bib27","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrneph.2013.169","article-title":"The podocyte slit diaphragm--from a thin grey line to a complex signalling hub","volume":"9","author":"Grahammer","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.isci.2022.104001_bib30","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cmet.2020.08.016","article-title":"Obesity-linked PPARgamma S273 phosphorylation promotes insulin resistance through growth differentiation factor 3","volume":"32","author":"Hall","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.isci.2022.104001_bib31","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.bbalip.2007.03.006","article-title":"PPARgamma in human and mouse physiology","volume":"1771","author":"Heikkinen","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.isci.2022.104001_bib32","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1681\/ASN.2014111080","article-title":"Nuclear factor erythroid 2-related factor 2 drives podocyte-specific expression of peroxisome proliferator-activated receptor gamma essential for resistance to crescentic GN","volume":"27","author":"Henique","year":"2016","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.isci.2022.104001_bib33","series-title":"Pioglitazone (Pio) in Pediatric Nephrotic Syndrome (NS)","first-page":"939","author":"Hunley","year":"2019"},{"key":"10.1016\/j.isci.2022.104001_bib34","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/sj.ki.5002248","article-title":"PPAR-gamma agonist protects podocytes from injury","volume":"71","author":"Kanjanabuch","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.isci.2022.104001_bib35","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1681\/ASN.2014111097","article-title":"Disease severity correlates with thrombotic capacity in experimental nephrotic syndrome","volume":"26","author":"Kerlin","year":"2015","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.isci.2022.104001_bib36","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1097-2765(00)80057-X","article-title":"Positionally cloned gene for a novel glomerular protein--nephrin--is mutated in congenital nephrotic syndrome","volume":"1","author":"Kestila","year":"1998","journal-title":"Mol.Cell"},{"key":"10.1016\/j.isci.2022.104001_bib37","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/S0002-9440(10)63590-0","article-title":"Nephrin promotes cell-cell adhesion through homophilic interactions","volume":"163","author":"Khoshnoodi","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.isci.2022.104001_bib38","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype","volume":"37","author":"Kim","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2022.104001_bib39","doi-asserted-by":"crossref","first-page":"1378175","DOI":"10.1155\/2017\/1378175","article-title":"Collaborative power of Nrf2 and PPARgamma activators against metabolic and drug-induced oxidative injury","volume":"2017","author":"Lee","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.isci.2022.104001_bib40","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.isci.2022.104001_bib41","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2471\/BLT.17.206441","article-title":"The global burden of kidney disease and the sustainable development goals","volume":"96","author":"Luyckx","year":"2018","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.isci.2022.104001_bib42","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1046\/j.1523-1755.2001.0590051899.x","article-title":"Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats","volume":"59","author":"Ma","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.isci.2022.104001_bib43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1476-5381.2010.01032.x","article-title":"The subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury","volume":"162","author":"Miglio","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.isci.2022.104001_bib44","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1476-5381.2012.02026.x","article-title":"Protective effects of peroxisome proliferator-activated receptor agonists on human podocytes: proposed mechanisms of action","volume":"167","author":"Miglio","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.isci.2022.104001_bib45","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrneph.2016.111","article-title":"Nephrotic syndrome: PCSK9: a target for hypercholesterolaemia in nephrotic syndrome","volume":"12","author":"Morris","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.isci.2022.104001_bib46","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1074\/jbc.272.12.8071","article-title":"Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists","volume":"272","author":"Mukherjee","year":"1997","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.isci.2022.104001_bib47","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1053\/meta.2001.26703","article-title":"Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria","volume":"50","author":"Nakamura","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.isci.2022.104001_bib48","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1161\/01.CIR.0000103683.99399.7E","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003","volume":"108","author":"Nesto","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.isci.2022.104001_bib49","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2022.104001_bib50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/PHMT.S100803","article-title":"Steroid-resistant nephrotic syndrome: past and current perspectives","volume":"8","author":"Nourbakhsh","year":"2017","journal-title":"Pediatr. Health Med. Ther."},{"key":"10.1016\/j.isci.2022.104001_bib51","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT-PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.isci.2022.104001_bib52","article-title":"Peroxisome proliferator activating receptor-gamma and the podocyte","author":"Platt","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.isci.2022.104001_bib53","author":"Radhakrishnan"},{"key":"10.1016\/j.isci.2022.104001_bib54","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.isci.2022.104001_bib55","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.kint.2018.11.008","article-title":"Management and treatment of glomerular diseases (part 2): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int."},{"key":"10.1016\/j.isci.2022.104001_bib56","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.ajkd.2009.11.013","article-title":"Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis","volume":"55","author":"Sarafidis","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.isci.2022.104001_bib57","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/ki.2012.180","article-title":"The pathophysiology of edema formation in the nephrotic syndrome","volume":"82","author":"Siddall","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.isci.2022.104001_bib58","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1681\/ASN.2015080885","article-title":"Sildenafil prevents podocyte injury via PPAR-gamma-mediated TRPC6 inhibition","volume":"28","author":"Sonneveld","year":"2017","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.isci.2022.104001_bib59","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/cam4.1354","article-title":"Pioglitazone and bladder cancer risk: a systematic review and meta-analysis","volume":"7","author":"Tang","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.isci.2022.104001_bib60","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.metabol.2004.06.016","article-title":"Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK\/Ta mice","volume":"53","author":"Tanimoto","year":"2004","journal-title":"Metabolism"},{"key":"10.1016\/j.isci.2022.104001_bib61","first-page":"914","article-title":"Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial","volume":"102","author":"Viscoli","year":"2017","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2022.104001_bib62","doi-asserted-by":"crossref","first-page":"e14515","DOI":"10.14814\/phy2.14515","article-title":"Nephrotic syndrome-associated hypercoagulopathy is alleviated by both pioglitazone and glucocorticoid which target two different nuclear receptors","volume":"8","author":"Waller","year":"2020","journal-title":"Physiol. Rep."},{"key":"10.1016\/j.isci.2022.104001_bib63","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1093\/bioinformatics\/bts356","article-title":"RSeQC: quality control of RNA-seq experiments","volume":"28","author":"Wang","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.isci.2022.104001_bib64","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s00467-017-3759-4","article-title":"Clinical outcomes and survival in pediatric patients initiating chronic dialysis: a report of the NAPRTCS registry","volume":"32","author":"Weaver","year":"2017","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.isci.2022.104001_bib65","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1038\/sj.ki.5000336","article-title":"Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis","volume":"69","author":"Yang","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.isci.2022.104001_bib66","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1681\/ASN.2008111138","article-title":"The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury","volume":"20","author":"Yang","year":"2009","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.isci.2022.104001_bib67","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-Jarvinen","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2022.104001_bib68","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/ndt\/gfr240","article-title":"Protective effects of PPARgamma agonist in acute nephrotic syndrome","volume":"27","author":"Zuo","year":"2012","journal-title":"Nephrol. Dial. Transplant."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004222002711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004222002711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:51:13Z","timestamp":1778899873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004222002711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2589004222002711"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2022.104001","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.09.14.459479","asserted-by":"object"}]},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective modulator of nuclear receptor PPAR\u03b3 with reduced adipogenic potential ameliorates experimental nephrotic syndrome","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2022.104001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"104001"}}